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Abstract
Geoffrey Burnstock completed a BSc at King’s College 
London and a PhD at University College London. He 
held postdoctoral fellowships with Wilhelm Feldberg 
(National Institute for Medical Research), Edith Bülbring 
(University of Oxford) and C. Ladd Prosser (University of   
Illinois). He was appointed to a Senior Lectureship in 
Melbourne University in 1959 and became Professor and 
Chairman of Zoology in 1964. In 1975 he became Head 
of Department of Anatomy and Developmental Biology 
at UCL and Convenor of the Center of Neuroscience. He   
has been Director of the Autonomic Neuroscience Insti­
tute at the Royal Free Hospital School of Medicine since 
1997. He was elected to the Australian Academy of Scien­ 
ces in 1971, the Royal Society in 1986, the Academy of   
Medical Sciences in 1998 and an Honorary Fellow of 
the Royal College of Surgeons and the Royal College of 
Physicians in 1999 and 2000. He was awarded the Royal   
Society Gold Medal in 2000. He is editor­in­chief of the 
journals Autonomic Neuroscience and Purinergic Signall­
ing and on the editorial boards of many other journals. 
Geoffrey Burnstock’s major research interest has been 
autonomic neurotransmission and he is best known for   
his seminal discovery of purinergic transmission and re­ 
ceptors, their signaling pathways and functional rele­
vance. He has supervised over 100 PhD and MD students 
and published over 1400 original papers, re­views   
and books. He was first in the Institute of Scientific In­
formation list of most cited scientists in Pharmacology 
and Toxicology from 1994­2004 [59.083 citations (March 
2011) and an h­index of 109].
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INTRODUCTION AND EDUCATIONAL 
EXPERIENCE
Geoffrey Burnstock (Figure 1) completed a BSc (Special) at 
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Figure 1  Geoffrey Burnstock, PhD, 
DSc, FAA, FRCS(Hon), FRCP(Hon),   
FMedSci, FRS, Professor, Autonomic 
Neuroscience Centre, Royal Free and 
University College, Medical School, 
Rowland Hill Street, London NW3 2PF, 
United Kingdom.from King’s College and University College London, Uni- 
versity of London (Supervisors: Professor JZ Young and 
Dr. Peggy Brown) in 1957. After moving to Melbourne in 
1959, he was awarded an Honorary MSc from Melbourne 
University in 1962 and later a DSc in 1971. He was award-
ed an Honorary MRCP in London in 1987 and twelve 
years later an Honorary FRCS in England and in 2000, 
FRCP.
My educational background has been extremely multi-
disciplinary, starting with zoology, then anatomy and de- 
velopmental biology, and then my most important con-
tributions are probably in physiology and pharmacology 
and, most recently, in pathology.
ACADEMIC STRATEGIES AND 
ACADEMIC GOALS
My academic strategies and goals have been to develop 
different aspects of autonomic neuroscience, with parti-
cular emphasis on purinergic signaling
[1]. In particular, I 
have tried to help bridge basic science, clinical medicine 
and the pharmaceutical industry.
ACADEMIC ACHIEVEMENTS
ATP was well established as an intracellular energy source 
involved in the Krebs cycle and other biochemical path-
ways, so our suggestion that it was also an extracellular sig-
naling molecule in the early 1970s
[2] was not widely accept-
ed for the next 20 years. However, when the receptors for   
ATP were cloned and characterized in the early 1990s, 
purinergic signaling was recognized and is now a rapidly 
expanding field
[3,4]. The initial studies describing purinergic 
neuromuscular transmission were carried out on the gut
[5].   
Non-adrenergic, non-cholinergic neuromuscular 
transmission
There was early recognition of atropine-resistant respon-
ses of the gastrointestinal tract to parasympathetic nerve 
stimulation. However, it was not until the early 1960s that   
autonomic transmission other than adrenergic and choli-
nergic was established. In 1963, electrical activity was recor-
ded in the guinea-pig taenia coli using the sucrose-gap   
technique and, after stimulation of the intramural nerves in 
the presence of adrenergic and cholinergic blocking agents,   
an inhibitory hyperpolarizing potential was observed
[6,7]. 
The hyperpolarizing responses were blocked by tetrodo-
toxin, a neurotoxin that prevents the action potential in 
nerves without affecting the excitability of smooth muscle 
cells, indicating their neurogenic nature and establishing 
them as inhibitory junction potentials in response to non-
adrenergic, non-cholinergic (NANC) nerves. This work 
was extended by an analysis of the mechanical responses 
to NANC nerve stimulation of the taenia coli
[8].
Purinergic signaling
The next step was to try to identify the transmitter released 
during NANC inhibitory transmission in the gut and by   
NANC excitatory transmission which we later identified 
in the urinary bladder. From the work of Jack Eccles and   
others, we knew that several criteria needed to be satisfied 
to establish a neurotransmitter: synthesis and storage in   
nerve terminals; release by a Ca
2+-dependent mechanism;   
mimicry of the nerve-mediated responses by the exogen-
ously applied transmitter; inactivation by ectoenzymes 
and/or neuronal uptake; and parallel block or potentiation 
of responses to stimulation by nerves and exogenously 
applied transmitter. We examined many different substan-
ces in the late 1960s, including amino acids, monoamines 
and neuropeptides, but none satisfied the criteria. However,   
on reading the literature, I discovered a seminal paper 
by Drury and Szent-Györgyi
[9] showing powerful extra-
cellular actions of purines on heart and blood vessels, 
papers by Feldberg showing extracellular actions of ATP 
on autonomic ganglia and a paper by Pamela Holton in   
1959
[10], which showed release of ATP during antidromic 
stimulation of sensory nerves supplying the rabbit ear 
artery. So we tried ATP and to our surprise it beautifully 
satisfied all the criteria needed to establish it as a transmit­
ter involved in NANC neurotransmission
[5]. In 1972, I pub- 
lished an article in Pharmacological Reviews formulating the 
purinergic neurotransmission hypothesis
[2]. My own view 
is that ATP, recognized as an early biological molecule, 
evolved both as an intracellular energy source and an 
extracellular signalling molecule. 
Cotransmission
During a sabbatical leave visiting the laboratory of Che Su 
and John Bevan at UCLA, we were disconcerted to find 
ATP release, not only from NANC intrinsic inhibitory en-
teric neurons, but also for sympathetic nerves supplying the   
taenia coli
[11]. However, this raised the question in my mind   
that ATP might be released as a cotransmitter from sym-
pathetic nerves and after discovering many hints in the 
literature, I formulated the cotransmitter hypothesis in 
1976 in a Commentary to Neuroscience
[12], which unfortuna-
tely also raised controversy because of the widely held 
concept called ‘Dales Principle’ although actually defined 
by Eccles, that one nerve only releases one transmitter. 
The electrical recordings Mollie Holman and I made 
during sympathetic neurotransmission in the guinea-pig 
vas deferens in the early 1960s showed excitatory junction 
potentials (EJPs) in response to single pulses that summed 
and facilitated, until at a critical depolarization, a spike 
was generated leading to contraction. However, what was 
puzzling was that receptor antagonists to noradrenaline 
(NA) as the transmitter recognized at that time in sympa-
thetic nerves did not block the EJPs, although bretylium, 
which prevents release of transmitter from sympathetic 
nerves, did reduce them. It was not until over 20 years 
later, when Peter Sneddon joined my laboratory in Lon- 
don, that we showed that α, β-methyleneATP, a slowly 
degradable analog of ATP that acts as a selective desen-
sitizer of the ATP receptor
[13], abolished the EJPs and 
spritzed ATP mimicked the EJP, but NA did not. Puriner-
gic cotransmission is now well established, not only in 
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motor and enteric nerves, and more recently ATP has 
been shown to be co-released with glutamate, GABA, do-
pamine, NA, 5-hydroxytryptamine and acetylcholine (ACh) 
in different populations of nerve fibers in the central 
nervous system
[14].
Receptors to purines and pyrimidines
Implicit in purinergic transmission is the existence of spe-
cific receptors. In 1978, I proposed a basis for distingui­
shing two types of purinergic receptors, one selective to 
adenosine (called P1), which was antagonized by methy- 
lxanthines, and the other selective for ATP/ADP (called 
P2)
[15]. A pharmacological basis for distinguishing two types   
of P2­purinoceptors, defined as P2X and P2Y, was pro­ 
posed in 1985
[16] and we were lucky that when P2 recep- 
  tors were cloned in the early 1990s and second messenger 
mechanisms examined, this subclassification was consis­ 
tent with P2X ion channel receptors and P2Y G protein­
coupled receptors
[17]. Currently 4 subtypes of P1 receptors 
are recognized, 7 subtypes of P2X receptors and 8 sub­ 
types of P2Y receptors, including some responsive to the   
pyrimidines, UTP and UDP
[18]. It was shown that three of 
the P2X receptor subunits combine to form cation pores 
either as homomultimers and heteromultimers, and more 
recently heterodimerization has been shown between P2Y 
receptor subtypes. Many non-neural as well as neuronal 
cells express multiple receptors
[19] and this poses problems 
about how they mediate interacting physiological events. It 
is becoming clear that the purinergic signaling system has 
an early evolutionary basis with fascinating recent studies 
showing cloned receptors in two primitive invertebrates, 
Dictyostelium and Schistosoma that resemble mammalian P2X 
receptors. 
Physiology of purinergic signaling
While early studies were largely focused on short-term   
signaling in such events as neurotransmission, neuromodu-
lation, secretion, chemoattraction and acute inflammation, 
there has been increasing interest in long-term (trophic) 
signaling involving cell proliferation, differentiation, 
motility and death in development, regeneration, wound 
healing, restenosis, epithelial cell turnover, cancer and age-
ing. For example, in blood vessels there is dual short-term 
control of vascular tone by ATP released as an excitatory   
cotransmitter from perivascular sympathetic nerves to act 
on P2X receptors on smooth muscle, while ATP released 
from endothelial cells during changes in blood flow (shear 
stress) and hypoxia acts on P2X and P2Y receptors on 
endothelial cells leading to production of nitric oxide and 
relaxation
[20]. In addition, there is long-term control of 
cell proliferation and differentiation, migration and death 
involved neovascularization, restenosis following angio-
plasty and atherosclerosis.
There is now abundant evidence for the widespread ex-
pression of purinoceptors in the gut involved in synaptic 
transmission and neuromodulation in the myenteric and 
submucous plexuses, in control of secretion, in peristaltic 
reflex activity and in mediation of colic pain
[21-23]. 
Purinergic neuropathology and therapeutic potential
Primitive sprouting of central neurons was shown in ex-
periments in which the enteric nervous system was trans- 
planted into the striatum of the brain
[24]. It was later shown   
that this was due to a growth factor, released from enteric 
glial cell acting synergistically with ATP, its breakdown pro-
duct adenosine and nitric oxide. It is suggested that similar 
synergistic activity of purines and growth factors might be 
involved in stem cell activity.
It was established early that ATP was a major cotrans-
mitter with ACh in parasympathetic nerves mediating con- 
traction of the urinary bladder of rodents. In healthy hu-
man bladder, the role of ATP as a cotransmitter is minor. 
However, in pathological conditions, such as interstitial 
cystitis, outflow obstruction and most types of neurogenic 
bladder, the purinergic component is increased to about 
40%. Similarly, in spontaneously hypertensive rats, there 
is a significantly greater cotransmitter role for ATP in 
sympathetic nerves.
P2X3 receptors were cloned in 1995 and shown to be   
largely located in small nociceptive sensory nerves that   
label with isolectin B4
[25,26]. Central projections are located   
in inner lamina 2 of the dorsal horn of the spinal cord and   
peripheral extensions in skin, tongue and visceral organs. 
A unifying purinergic hypothesis for the initiation of pain 
was published
[27] and a hypothesis describing purinergic 
mechanosensory transduction in visceral organs in 1999
[28],   
where ATP, released from lining epithelial cells during 
distension, acts on P2X3 and P2X2/3 receptors in subepi-
thelial sensory nerve endings to send nociceptive messages 
via sensory ganglia to the pain centers in the brain. Sup-
porting evidence including: epithelial release of ATP; 
immuno­localization of P2X3 receptors on subepithelial 
nerves; and activity recorded in sensory nerves during 
distension that is mimicked by ATP and reduced by P2X3 
receptor antagonists, has been reported in the bladder,   
ureter and gut
[29]. Purinergic mechanosensory transduc-
tion is also involved in urine voiding. There is also strong 
interest in the potential roles of purinergic signaling in 
trauma and ischemia, neurodegenerative conditions inclu-
ding Alzheimer’s, Parkinson’s and Huntington’s diseases 
and in multiple sclerosis and amyotrophic lateral sclerosis. 
CONCLUSION
Purinergic signaling is now widely accepted for its in-
volvement in a wide spectrum of physiological and patho-
physiological activities
[3,30]. This was recognised by the 
Award for ‘Lifetime Achievement in Digestive Sciences’, 
the Janssen Award in Gastroenterology 2000, The Royal 
Society Gold Medal, 2000, the Copernicus Gold Medal, 
Ferrara, 2009, the British Neuroscience Annual Award 
for ‘Outstanding Contributions to British Neuroscience’ 
2009 and the Gaddum Memorial Award of the British 
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